Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention (R21 Clinical Trial Optional)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

View website    Save

Next deadline: Oct 8, 2021 (Letter of inquiry)

Later deadlines: Nov 8, 2021 (Full proposal)

Grant amount: Up to US $275,000

Fields of work: Cancer/Oncology

Applicant type: Organizations

Funding uses: Biomedical

Location of project: Anywhere in the world

Location of residency: Anywhere in the world

Overview:

NOTE: 

  • Applications are due by 5 pm submitter's local time. 
  • Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.

The overall objective of this Funding Opportunity Announcement (FOA) is to support innovative research on adducts to cellular macromolecules as indicators of exposures to endogenous and exogenous cancer risk factors relevant to exposures in human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts.

The ultimate goal is to discover and characterize the utility of adductomic-based exposure indicators for:

  • Cancer detection,
  • Cancer prevention, and/or
  • Assessing cancer risks.

In well-justified cases, innovative studies using the adductomic approaches in the context of cancer etiology and/or gene-environment interaction research may also be appropriate. For projects intended for NIEHS support, the focus may be on innovative technology and method development.

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.

Eligibility:


Other Opportunities

This page was last reviewed April 24, 2019 and last updated April 24, 2019